Direct oral anticoagulants and vitamin K antagonists are linked to differential profiles of cardiac function and lipid metabolism

Lisa Eggebrecht, Juergen H. Prochaska, Sven-Oliver Troebs, Soeren Schwuchow-Thonke, Sebastian Goebel, Simon Diestelmeier, Andreas Schulz, Natalie Arnold, Marina Panova-Noeva, Thomas Koeck, Steffen Rapp, Tommaso Gori, Karl J. Lackner, Hugo ten Cate, Thomas Muenzel, Philipp Sebastian Wild*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)

Abstract

BackgroundExperimental data indicate that direct acting oral anticoagulants (DOAC) and vitamin K antagonists (VKA) may exert differential effects on cardiovascular disease.MethodsData from the prospective, observational, single-center MyoVasc Study were used to examine associations of DOAC as compared to VKA with subclinical markers of cardiovascular disease, cardiac function, and humoral biomarkers in heart failure (HF).ResultsMultivariable analysis adjusted for age, sex, traditional cardiovascular risk factors, comorbidities, and medications with correction for multiple testing demonstrated that DOAC therapy was among all investigated parameters an independent significant predictor of better diastolic function (E/E: -0.24 [-0.36/-0.12]; P

Original languageEnglish
Pages (from-to)787-796
Number of pages10
JournalClinical research in cardiology
Volume108
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Anticoagulation
  • Direct oral anticoagulants
  • Vitamin K antagonist
  • Cardiac function
  • Lipids and lipid protein metabolism
  • DIRECT THROMBIN INHIBITION
  • FACTOR-XA
  • ATRIAL-FIBRILLATION
  • DABIGATRAN ETEXILATE
  • RIVAROXABAN
  • PROGRESSION
  • RISK
  • FIBROBLASTS
  • WARFARIN
  • DISEASE

Cite this